Professor Naveed Sattar, Professor of Cardiometabolic Medicine at the School of Cardiovascular & Metabolic Health at the ...

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide.

As one endocrinologist told me, if he could not be at this year's EASD meeting (the annual congress of the European Association for the Study of Diabetes) in person, he would simply take part via ...

At a meeting of the Easton Area school board, Northampton Community College presented an overview of its $81 million budget ...

Berberine ursodeoxycholate (HTD1801) showed potential as a treatment option for patients with type 2 diabetes (T2D), with significant reductions in A1c and fasting plasma glucose levels. The ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...